© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 1, 19-29,
January 1, 2003
© 2003 Oxford University Press
REVIEW |
Placebo Effects in Oncology
Affiliations of authors: G. Chvetzoff, Department of Medical Oncology, Centre Léon Bérard, Lyon, France; I. F. Tannock, Princess Margaret Hospital, Toronto, Ontario, Canada.
Correspondence to: I. F. Tannock, M.D., Ph.D., Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave., Toronto, Ontario M5G 2M9, Canada (e-mail: ian.tannock{at}uhn.on.ca).
Background: Previous studies have suggested that placebo treatment can have positive effects on a variety of disorders and disease-related symptoms. However, the methodology used to collect and interpret the data may not have been ideal, because the studies were not double-blinded or the endpoints were not properly validated. The purpose of the present study was to determine the probability of improvement in symptoms or quality of life and tumor response in cancer patients treated with placebos in randomized controlled trials. We hypothesized that administration of placebos would improve symptom control and quality of life but would not lead to tumor response. Methods: We reviewed reports of randomized controlled trials in which there was a placebo arm (37 trials) or a best supportive care (BSC) arm (10 trials). Results: In trials that assessed average responses for patients in the placebo arm, improvements in average levels of pain were reported in two of six trials and in appetite, in one of seven trials. No improvements in average levels of weight gain (six trials), in quality of life (as assessed by patients; 10 trials), or in performance status (as assessed by physicians; nine trials) were reported. In trials that assessed response to a placebo in individual patients, 0%–21% of patients showed reduced pain or decreased analgesic intake, 8%–27% of patients showed appetite improvement, 7%–17% of patients showed weight gain, and 6%–14% of patients showed improvement in performance status. Quality of life for individual patients was not reported in any trial. Tumor response assessed by World Health Organization criteria was observed in 10 (2.7%) of 375 patients (seven trials total). Response as assessed by a serum marker was observed in 1 (1.7%) of 60 patients (two trials total). The probability of symptom improvement in patients receiving BSC was generally similar to that in patients receiving placebo, although no improvement in pain and only one tumor response among 191 patients (five trials) were reported. Conclusion: In randomized double-blinded, placebo-controlled trials, presumably with minimum sources of bias, placebos are sometimes associated with improved control of symptoms such as pain and appetite but rarely with positive tumor response. Substantial improvements in symptoms and quality of life are unlikely to be due to placebo effects.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Strasser, D. Luftner, K. Possinger, G. Ernst, T. Ruhstaller, W. Meissner, Y.-D. Ko, M. Schnelle, M. Reif, and T. Cerny Comparison of Orally Administered Cannabis Extract and Delta-9-Tetrahydrocannabinol in Treating Patients With Cancer-Related Anorexia-Cachexia Syndrome: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial From the Cannabis-In-Cachexia-Study-Group J. Clin. Oncol., July 20, 2006; 24(21): 3394 - 3400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Yates, S. Aranda, M. Hargraves, B. Mirolo, A. Clavarino, S. McLachlan, and H. Skerman Randomized Controlled Trial of an Educational Intervention for Managing Fatigue in Women Receiving Adjuvant Chemotherapy for Early-Stage Breast Cancer J. Clin. Oncol., September 1, 2005; 23(25): 6027 - 6036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Mattox Treatment of Unintentional Weight Loss in Patients With Cancer Nutr Clin Pract, August 1, 2005; 20(4): 400 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Browman Standards of Proof, Standards of Practice, and Proof of Standards: A Tale of Two Trials J. Clin. Oncol., April 20, 2005; 23(12): 2583 - 2585. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Tannock Features of a High Quality Phase 3 Trial Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 207 - 210. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dahele and K. Fearon Research methodology: cancer cachexia syndrome Palliative Medicine, July 1, 2004; 18(5): 409 - 417. [Abstract] [PDF]
|
|
|
|
 |
|
 J. L. Mulshine, J. C. Atkinson, R. O. Greer, V. A. Papadimitrakopoulou, C. Van Waes, S. Rudy, J. W. Martin, S. M. Steinberg, D. J. Liewehr, I. Avis, et al. Randomized, Double-Blind, Placebo-Controlled Phase IIB Trial of the Cyclooxygenase Inhibitor Ketorolac as an Oral Rinse in Oropharyngeal Leukoplakia Clin. Cancer Res., March 1, 2004; 10(5): 1565 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Temple Implications of Effects in Placebo Groups J Natl Cancer Inst, January 1, 2003; 95(1): 2 - 3. [Full Text] [PDF]
|
|